Showing 683 results
-
Media Release /- Phase III PREVENT study met 52-week primary endpoint of ASAS40, showing a sustained response in patients with non-radiographic axial spondyloarthritis (nr-axSpA)(1)- Novartis plans FDA submission…
-
Media Release /
-
Media Release /BASEL, Switzerland, Sept. 19, 2019 /PRNewswire/ -- New interim data from SPR1NT study supports critical importance of early intervention in pre-symptomatic SMA patients, leading to age‑appropriate…
-
Media Release /
-
Media Release /- Results from PROVE-HF trial show significant improvements in measures of cardiac structure and function at six months and one year in heart failure with reduced ejection fraction (HFrEF) patients;(…
-
Media Release /
-
Media Release /- My Home in Sight, developed in partnership with six leading patient advocacy organizations, provides five key principles of adapting spaces in the home to support those impacted by wet AMD and…
-
Media Release /
-
Media Release /- FDA grants crizanlizumab Priority Review based on Phase II data showing prevention of vaso-occlusive crises (VOCs) in patients with sickle cell disease, shortening FDA review to six months from…
-
Media Release /
